Roundtable
Roundtable
Advertisement
Pedro Barata, MDCRPC | October 2, 2024
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
View More
Pedro Barata, MDProstate Cancer | October 2, 2024
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
Pedro Barata, MDProstate Cancer | October 2, 2024
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
Pedro Barata, MDProstate Cancer | October 2, 2024
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
Andrew Laccetti, MD, MSCRPC | September 25, 2024
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Andrew Laccetti, MD, MSCRPC | September 25, 2024
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
Andrew Laccetti, MD, MSCRPC | September 25, 2024
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
Andrew Laccetti, MD, MSnmHSPC | September 25, 2024
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Andrew Laccetti, MD, MSCRPC | September 25, 2024
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
Andrew Laccetti, MD, MSmHSPC | September 25, 2024
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
Jigarkumar Parikh, MD, MBBSmCSPC | September 17, 2024
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
Laurence Albiges, MD, PhDnccRCC | July 26, 2024
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
Advertisement
Advertisement
Advertisement